CoChat

Principles of the activin receptor signaling pathway and its inhibition

Open access
Lodberg, Andreas · 2021 · Cytokine & Growth Factor Reviews
Cited by 62

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

This review captures the anabolic and stimulatory effects observed with inhibition of the transforming growth factor β superfamily in muscle, blood, and bone. New medicinal substances that rectify activin, myostatin, and growth differentiation factor 11 signaling give hope to the many whose lives are affected by deterioration of these tissues. The review first covers the origin, structure, and common pathway of activins, myostatin, and growth differentiation factor 11 along with the pharmacodynamics of the new class of molecules designed to oppose the activin receptor signaling pathway. Current terminology surrounding this new class of molecules is inconsistent and does not infer functionality. Adopting inhibitors of the activin receptor signaling pathway (IASPs) as a generic term is proposed because it encapsulates the molecular mechanisms along the pathway trajectory. To conclude, a pragmatic classification of IASPs is presented that integrates functionality and side effects based on the data available from animals and humans. This provides researchers and clinicians with a tool to tailor IASPs therapy according to the need of projects or patients and with respect to side effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cytogfr.2021.04.001

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 145

  1. Kamiya, 2017, Sarcopenia: prevalence and prognostic implications in elderly patients with cardiovascular disease, JCSM Clin. Reports, 2, 1, 10.17987/jcsm-cr.v2i2.41 · DOI
  2. Trierweiler, 2018, Sarcopenia: A chronic complication of type 2 diabetes mellitus, Diabetol. Metab. Syndr., 10, 25, 10.1186/s13098-018-0326-5 · DOI · Paper page
  3. De Souza, 2017, Sarcopenia in patients with chronic kidney disease not yet on dialysis: analysis of the prevalence and associated factors, PLoS One, 12, 10.1371/journal.pone.0176230 · DOI · Paper page
  4. Benz, 2019, Sarcopenia in COPD: a systematic review and meta-analysis, Eur. Respir. Rev., 28, 10.1183/16000617.0049-2019 · DOI · Paper page
  5. Colón, 2018, Muscle and bone mass loss in the elderly population: advances in diagnosis and treatment, J. Biomed. Syd. (Syd), 3, 40
  6. Tsekoura, 2017, Sarcopenia and its impact on quality of life, 213, 10.1007/978-3-319-57379-3_19 · DOI · Paper page
  7. McDonald, 1991, New protein fold revealed by a 2.3-Å resolution crystal structure of nerve growth factor, Nature, 354, 411, 10.1038/354411a0 · DOI · Paper page
  8. Cash, 2009, The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding, EMBO J., 28, 2662, 10.1038/emboj.2009.205 · DOI · Paper page
  9. Gray, 1990, Requirement for activin a and transforming growth factor-β1 pro-regions in homodimer assembly, Science (80-.), 247, 1328, 10.1126/science.2315700 · DOI · Paper page
  10. Takahashi, 1995, Localization of furin to the trans-Golgi network and recycling from the cell surface involves Ser and Tyr residues within the cytoplasmic domain, J. Biol. Chem., 270, 28397, 10.1074/jbc.270.47.28397 · DOI
  11. Le, 2018, Tolloid cleavage activates latent GDF8 by priming the pro‐complex for dissociation, EMBO J., 37, 384, 10.15252/embj.201797931 · DOI
  12. Mi, 2015, Structure of bone morphogenetic protein 9 procomplex, Proc. Natl. Acad. Sci. U. S. A., 112, 3710, 10.1073/pnas.1501303112 · DOI · Paper page
  13. Wolfman, 2003, Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases, Proc. Natl. Acad. Sci. U. S. A., 100, 15842, 10.1073/pnas.2534946100 · DOI · Paper page
  14. Ling, 1986, Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin, Nature, 321, 779, 10.1038/321779a0 · DOI · Paper page
  15. Lewis, 2000, Betaglycan binds inhibin and can mediate functional antagonism of activin signalling, Nature, 404, 411, 10.1038/35006129 · DOI · Paper page
  16. Gold, 2009, Activin C antagonizes activin A in vitro and overexpression leads to pathologies in vivo, Am. J. Pathol., 174, 184, 10.2353/ajpath.2009.080296 · DOI
  17. McPherron, 1997, Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member, Nature, 387, 83, 10.1038/387083a0 · DOI · Paper page
  18. Nakashima, 1999, Expression of growth/differentiation factor 11, a new member of the BMP/TGFbeta superfamily during mouse embryogenesis, Mech. Dev., 80, 185, 10.1016/S0925-4773(98)00205-6 · DOI · Paper page
  19. Suragani, 2014, Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis, Nat. Med., 20, 408, 10.1038/nm.3512 · DOI · Paper page
  20. Walker, 2017, Structural basis for potency differences between GDF8 and GDF11, BMC Biol., 15, 19, 10.1186/s12915-017-0350-1 · DOI · Paper page
  21. Pepinsky, 2017, A prodomain fragment from the proteolytic activation of growth differentiation factor 11 remains associated with the mature growth factor and keeps it soluble, Biochemistry, 56, 4405, 10.1021/acs.biochem.7b00302 · DOI
  22. Walker, 2018, Molecular characterization of latent GDF8 reveals mechanisms of activation, Proc. Natl. Acad. Sci. U. S. A., 115, E866, 10.1073/pnas.1714622115 · DOI
  23. Schafer, 2016, Quantification of GDF11 and myostatin in human aging and cardiovascular disease, Cell Metab., 23, 10.1016/j.cmet.2016.05.023 · DOI · Paper page
  24. Lakshman, 2009, Measurement of myostatin concentrations in human serum: circulating concentrations in young and older men and effects of testosterone administration, Mol. Cell. Endocrinol., 302, 26, 10.1016/j.mce.2008.12.019 · DOI
  25. Sugino, 1988, Identification of a specific receptor for erythroid differentiation factor on follicular granulosa cell, J. Biol. Chem., 263, 15249, 10.1016/S0021-9258(19)37578-7 · DOI
  26. Lebrun, 1997, Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation, Mol. Cell. Biol., 17, 1682, 10.1128/MCB.17.3.1682 · DOI · Paper page
  27. Luo, 1997, Positive and negative regulation of type II TGF-beta receptor signal transduction by autophosphorylation on multiple serine residues, EMBO J., 16, 1970, 10.1093/emboj/16.8.1970 · DOI
  28. Andersson, 2006, Growth differentiation factor 11 signals through the transforming growth factor-β receptor ALK5 to regionalize the anterior-posterior axis, EMBO Rep., 7, 831, 10.1038/sj.embor.7400752 · DOI · Paper page
  29. Thompson, 2003, Structures of an ActRIIB:activin a complex reveal a novel binding mode for TGF-β ligand:receptor interactions, EMBO J., 22, 1555, 10.1093/emboj/cdg156 · DOI · Paper page
  30. Gray, 2000, Identification of a binding site on the type II activin receptor for activin and inhibin, J. Biol. Chem., 275, 3206, 10.1074/jbc.275.5.3206 · DOI
  31. Massague, 2005, Smad transcription factors, Genes Dev., 19, 2783, 10.1101/gad.1350705 · DOI · Paper page
  32. Loomans, 2016, Activin receptor-like kinases: a diverse family playing an important role in cancer, Am. J. Cancer Res., 6, 2431
  33. Bernard, 2006, Activin B can signal through both ALK4 and ALK7 in gonadotrope cells, Reprod. Biol. Endocrinol., 4, 52, 10.1186/1477-7827-4-52 · DOI · Paper page
  34. Tsuchida, 2004, Activin isoforms signal through type I receptor serine/threonine kinase ALK7, Mol. Cell. Endocrinol., 220, 59, 10.1016/j.mce.2004.03.009 · DOI
  35. Rebbapragada, 2003, Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis, Mol. Cell. Biol., 23, 7230, 10.1128/MCB.23.20.7230-7242.2003 · DOI · Paper page
  36. Attisano, 1996, Signal transduction by members of the transforming growth factor-beta superfamily, Cytokine Growth Factor Rev., 7, 327, 10.1016/S1359-6101(96)00042-1 · DOI
  37. Inman, 2002, SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7, Mol. Pharmacol., 62, 65, 10.1124/mol.62.1.65 · DOI · Paper page
  38. Herbertz, 2015, Clinical development of galunisertib (Ly2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway, Drug Des. Devel. Ther., 9, 4479
  39. Kidane, 2005, Recent advances in small molecule drug delivery, Curr. Opin. Chem. Biol., 9, 347, 10.1016/j.cbpa.2005.06.006 · DOI
  40. Fisher, 1996, Treatment of septic shock with the tumor necrosis factor receptor:fc fusion protein, N. Engl. J. Med., 334, 1697, 10.1056/NEJM199606273342603 · DOI · Paper page
  41. Pearsall, 2008, A soluble activin type IIA receptor induces bone formation and improves skeletal integrity, Proc. Natl. Acad. Sci. U. S. A., 105, 7082, 10.1073/pnas.0711263105 · DOI · Paper page
  42. Sherman, 2013, Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a Novel erythropoietic agent, in healthy postmenopausal women, J. Clin. Pharmacol., 53, 1121, 10.1002/jcph.160 · DOI
  43. Kanehisa, 2000, KEGG: Kyoto Encyclopedia of Genes and Genomes, Nucleic Acids Res., 28, 27, 10.1093/nar/28.1.27 · DOI · Paper page
  44. Chen, 2016, Pharmacokinetics and exposure-response of luspatercept in patients with beta-thalassemia: preliminary results from phase 2 studies, Blood, 128, 2463, 10.1182/blood.V128.22.2463.2463 · doi:10.1182/blood.v128.22.2463.2463
  45. Attie, 2014, A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers, Am. J. Hematol., 89, 766, 10.1002/ajh.23732 · DOI · Paper page
  46. Fenaux, 2020, Luspatercept in patients with lower-risk myelodysplastic syndromes, N. Engl. J. Med., 382, 140, 10.1056/NEJMoa1908892 · DOI · Paper page
  47. Mori-Yoshimura, 2019, Late phase II/III study of BYM338 in patients with sporadic inclusion body myositis (RESILIENT): japanese cohort data, Clin. Neurol., 59, 806
  48. Polkey, 2018, Activin type II receptor blockade for treatment of muscle depletion in COPD: a randomized trial, Am. J. Respir. Crit. Care Med.
  49. Pearsall, 2019, Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease, Sci. Rep., 9, 11392, 10.1038/s41598-019-47818-w · DOI
  50. Castonguay, 2019, Follistatin-288-Fc fusion protein promotes localized growth of skeletal muscle, J. Pharmacol. Exp. Ther., 368, 435, 10.1124/jpet.118.252304 · DOI
  51. Lerch, 2007, Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions, J. Biol. Chem., 282, 15930, 10.1074/jbc.M700737200 · DOI · Paper page
  52. Statland, 2018, FSHD / OPMD / EDMD /. DMI: P.365: Results for a dose-escalation phase 2 study to evaluate ACE-083, a local muscle therapeutic, in patients with facioscapulohumeral muscular dystrophy, Neuromuscul. Disord., 28, S140, 10.1016/j.nmd.2018.06.413 · doi:10.1016/j.nmd.2018.06.413
  53. Shy, 2018, CMT AND NEUROGENIC DISEASE: P.339: preliminary phase 2 results for ACE-083, local muscle therapeutic, in patients with CMT1 and CMTX, Neuromuscul. Disord., 28, S132, 10.1016/j.nmd.2018.06.387 · doi:10.1016/j.nmd.2018.06.387
  54. Yaden, 2014, Follistatin: a novel therapeutic for the improvement of muscle regeneration, J. Pharmacol. Exp. Ther., 349, 355, 10.1124/jpet.113.211169 · DOI
  55. Lodberg, 2019, A follistatin-based molecule increases muscle and bone mass without affecting the red blood cell count in mice, FASEB J., 33, 6001, 10.1096/fj.201801969RR · DOI
  56. Wagner, 2008, A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy, Ann. Neurol., 63, 561, 10.1002/ana.21338 · DOI · Paper page
  57. Zhang, 2011, Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease, FASEB J., 25, 1653, 10.1096/fj.10-176917 · DOI · Paper page
  58. Bhattacharya, 2018, Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an antimyostatin monoclonal antibody, in healthy subjects, Clin. Pharmacol. Drug Dev., 7, 484, 10.1002/cpdd.386 · DOI · Paper page
  59. Kalra, 2019, P.126SRK-015, a fully human monoclonal antibody inhibiting myostatin activation, offers sustained target engagement across multiple species, including humans, Neuromuscul. Disord., 29, S85, 10.1016/j.nmd.2019.06.182 · doi:10.1016/j.nmd.2019.06.182
  60. Long, 2019, Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy, Hum. Mol. Genet., 28, 1076, 10.1093/hmg/ddy382 · DOI · Paper page
  61. Whittemore, 2003, Inhibition of myostatin in adult mice increases skeletal muscle mass and strength, Biochem. Biophys. Res. Commun., 300, 965, 10.1016/S0006-291X(02)02953-4 · DOI · Paper page
  62. Pistilli, 2011, Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy, Am. J. Pathol., 178, 1287, 10.1016/j.ajpath.2010.11.071 · DOI
  63. Alyodawi, 2019, Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling, J. Cachexia Sarcopenia Muscle, 10, 662, 10.1002/jcsm.12404 · DOI
  64. Sepulveda, 2015, Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy, Sci. Rep., 5, 17535, 10.1038/srep17535 · DOI
  65. Zhou, 2010, Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival, Cell, 142, 531, 10.1016/j.cell.2010.07.011 · DOI · Paper page
  66. Meier, 2020, Inhibition of the activin receptor signaling pathway: a novel intervention against osteosarcoma, Cancer Med., cam4.3581
  67. Yaffe, 1977, Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle, Nature, 270, 725, 10.1038/270725a0 · DOI · Paper page
  68. Lokireddy, 2011, Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteins, Am. J. Physiol. - Cell Physiol., 301, C1316, 10.1152/ajpcell.00114.2011 · DOI · Paper page
  69. Welle, 2009, Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice, Am. J. Physiol. - Endocrinol. Metab., 296, E567, 10.1152/ajpendo.90862.2008 · DOI · Paper page
  70. McFarlane, 2006, Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism, J. Cell. Physiol., 209, 501, 10.1002/jcp.20757 · DOI · Paper page
  71. Yang, 2007, Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3β pathway and is antagonized by insulin-like growth factor, J. Biol. Chem., 282, 3799, 10.1074/jbc.M610185200 · DOI · Paper page
  72. Asfour, 2018, Myogenic regulatory factors: the orchestrators of myogenesis after 30 years of discovery, Exp. Biol. Med., 243, 118, 10.1177/1535370217749494 · DOI · Paper page
  73. Berkes, 2005, MyoD and the transcriptional control of myogenesis, Semin. Cell Dev. Biol., 16, 585, 10.1016/j.semcdb.2005.07.006 · DOI · Paper page
  74. Langley, 2002, Myostatin inhibits myoblast differentiation by down-regulating MyoD expression, J. Biol. Chem., 277, 49831, 10.1074/jbc.M204291200 · DOI · Paper page
  75. Vermeulen, 2003, The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer, Cell Prolif., 36, 131, 10.1046/j.1365-2184.2003.00266.x · DOI · Paper page
  76. Varshavsky, 2017, The ubiquitin system, autophagy, and regulated protein degradation, Annu. Rev. Biochem., 86, 123, 10.1146/annurev-biochem-061516-044859 · DOI · Paper page
  77. Foletta, 2011, The role and regulation of MAFbx/atrogin-1 and MuRFl in skeletal muscle atrophy, Pflugers Arch. Eur. J. Physiol., 461, 325, 10.1007/s00424-010-0919-9 · DOI · Paper page
  78. Polge, 2018, A muscle-specific MuRF1-E2 network requires stabilization of MuRF1-E2 complexes by telethonin, a newly identified substrate, J. Cachexia Sarcopenia Muscle, 9, 129, 10.1002/jcsm.12249 · DOI
  79. Lee, 2011, Myostatin induces autophagy in skeletal muscle in vitro, Biochem. Biophys. Res. Commun., 415, 632, 10.1016/j.bbrc.2011.10.124 · DOI
  80. Lee, 2012, Role of satellite cells versus myofibers in muscle hypertrophy induced by inhibition of the myostatin/activin signaling pathway, Proc. Natl. Acad. Sci. U. S. A., 109, 10.1073/pnas.1206410109 · DOI · Paper page
  81. Bachettini, 2020, Sarcopenia as a mortality predictor in community-dwelling older adults: a comparison of the diagnostic criteria of the European Working Group on Sarcopenia in Older People, Eur. J. Clin. Nutr., 74, 573, 10.1038/s41430-019-0508-8 · DOI
  82. Padhi, 2014, Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer, J. Clin. Endocrinol. Metab., 99, E1967, 10.1210/jc.2014-1271 · DOI · Paper page
  83. Woodhouse, 2016, STUDY INVESTIGATORS, a phase 2 randomized study investigating the efficacy and safety of myostatin antibody LY2495655 versus placebo in patients undergoing elective total hip arthroplasty, J. Frailty Aging, 5, 62
  84. Becker, 2015, Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial, Lancet Diabetes Endocrinol., 3, 948, 10.1016/S2213-8587(15)00298-3 · DOI · Paper page
  85. Schols, 1995, Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease: a placebo-controlled randomized trial, Am. J. Respir. Crit. Care Med., 152, 1268, 10.1164/ajrccm.152.4.7551381 · DOI · Paper page
  86. Casaburi, 2004, Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease, Am. J. Respir. Crit. Care Med., 170, 870, 10.1164/rccm.200305-617OC · DOI · Paper page
  87. Sharma, 2008, Anabolic steroids in COPD: a review and preliminary results of a randomized trial, Chron. Respir. Dis., 5, 169, 10.1177/1479972308092350 · DOI
  88. Glasser, 2018, Locally acting ACE-083 increases muscle volume in healthy volunteers, Muscle Nerve, 10.1002/mus.26113 · DOI · Paper page
  89. Ruckle, 2009, Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women, J. Bone Miner. Res., 24, 744, 10.1359/jbmr.081208 · DOI · Paper page
  90. Carrancio, 2014, An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin, Br. J. Haematol., 165, 870, 10.1111/bjh.12838 · DOI
  91. Valent, 2018, Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts, Haematologica, 103, 1593, 10.3324/haematol.2018.192518 · DOI
  92. Oikonomidou, 2018, What can we learn from ineffective erythropoiesis in thalassemia?, Blood Rev., 32, 130, 10.1016/j.blre.2017.10.001 · DOI
  93. Blank, 2015, TGF-β signaling in the control of hematopoietic stem cells, Blood, 125, 3542, 10.1182/blood-2014-12-618090 · DOI · Paper page
  94. Zhou, 2008, Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS, Blood, 112, 3434, 10.1182/blood-2008-02-139824 · DOI · Paper page
  95. Bhagat, 2013, MiR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling, Blood, 121, 2875, 10.1182/blood-2011-12-397067 · DOI · Paper page
  96. Yu, 1987, Importance of FSH-releasing protein and inhibin in erythrodifferentiation, Nature, 330, 765, 10.1038/330765a0 · DOI · Paper page
  97. Broxmeyer, 1988, Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin, Proc. Natl. Acad. Sci. U. S. A., 85, 9052, 10.1073/pnas.85.23.9052 · DOI
  98. Shiozaki, 1998, Activin A: A commitment factor in erythroid differentiation, Biochem. Biophys. Res. Commun., 242, 631, 10.1006/bbrc.1997.8020 · DOI
  99. Guerra, 2019, Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of beta-thalassemia, Blood, 10.1182/blood.2019001057 · DOI
  100. Goldstein, 2019, Steady-state and regenerative hematopoiesis occur normally in mice in the absence of GDF11, Blood, 10.1182/blood.2019002066 · DOI
  101. Langdon, 2015, RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in Hepcidin transgenic mice, Am. J. Hematol., 90, 8, 10.1002/ajh.23856 · DOI
  102. Iancu-Rubin, 2013, Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap, Exp. Hematol., 41, 155, 10.1016/j.exphem.2012.12.002 · DOI
  103. Crosby, 1997, Guidelines for red blood cell and plasma transfusion for adults and children, CMAJ, 156, S1
  104. Van Der Putten, 2008, Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure, Nat. Clin. Pract. Nephrol., 4, 47, 10.1038/ncpneph0655 · DOI · Paper page
  105. Gilliss, 2011, Reducing noninfectious risks of blood transfusion, Anesthesiology, 115, 635, 10.1097/ALN.0b013e31822a22d9 · DOI · Paper page
  106. Lodberg, 2018, A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia, Bone, 110, 326, 10.1016/j.bone.2018.02.026 · DOI
  107. Bonucci, 2012, Bone mineralization, Front. Biosci., 17, 100, 10.2741/3918 · DOI
  108. Long, 2012, Building strong bones: molecular regulation of the osteoblast lineage, Nat. Rev. Mol. Cell Biol., 13, 27, 10.1038/nrm3254 · DOI · Paper page
  109. Väänänen, 2008, Osteoclast lineage and function, Arch. Biochem. Biophys., 473, 132, 10.1016/j.abb.2008.03.037 · DOI · Paper page
  110. Eijken, 2007, The activin A-follistatin system: potent regulator of human extracellular matrix mineralization, FASEB J., 21, 2949, 10.1096/fj.07-8080com · DOI · Paper page
  111. Ikenoue, 1999, Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells, J. Cell. Biochem., 75, 206, 10.1002/(SICI)1097-4644(19991101)75:2<206::AID-JCB3>3.0.CO;2-T · DOI · Paper page
  112. Liu, 2016, GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation, Nat. Commun., 7, 12794, 10.1038/ncomms12794 · DOI · Paper page
  113. Sakai, 1993, Activin enhances osteoclast-like cell formation in vitro, Biochem. Biophys. Res. Commun., 195, 39, 10.1006/bbrc.1993.2006 · DOI
  114. Fuller, 2000, Activin A is an essential cofactor for osteoclast induction, Biochem. Biophys. Res. Commun., 268, 2, 10.1006/bbrc.2000.2075 · DOI
  115. Fowler, 2015, Activin A inhibits RANKL-mediated osteoclast formation, movement and function in murine bone marrow macrophage cultures, J. Cell. Sci., 128, 683
  116. Hamrick, 2003, Increased bone mineral density in the femora of GDF8 knockout mice, Anat. Rec., 272A, 388, 10.1002/ar.a.10044 · DOI · Paper page
  117. Hamrick, 2006, Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise, J. Bone Miner. Res., 21, 477, 10.1359/JBMR.051203 · DOI · Paper page
  118. Lotinun, 2010, A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys, Bone, 46, 1082, 10.1016/j.bone.2010.01.370 · DOI
  119. Jerome, 1999, Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis), Bone, 25, 301, 10.1016/S8756-3282(99)00166-0 · DOI
  120. Doyle, 2018, Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption, Osteoporos. Int., 29, 685, 10.1007/s00198-017-4323-6 · DOI
  121. Brent, 2020, Activin type IIA decoy receptor and intermittent parathyroid hormone in combination overturns the bone loss in disuse-osteopenic mice, Bone, 142
  122. Abdulkadyrov, 2014, Sotatercept in patients with osteolytic lesions of multiple myeloma, Br. J. Haematol., 165, 814, 10.1111/bjh.12835 · DOI
  123. Tillet, 2015, Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia, Front. Genet., 5, 456, 10.3389/fgene.2014.00456 · DOI
  124. Campbell, 2017, Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial, Muscle Nerve, 55, 458, 10.1002/mus.25268 · DOI · Paper page
  125. Gregory, 2004, Regulation of gonadotropins by inhibin and activin, Semin. Reprod. Med., 22, 253, 10.1055/s-2004-831901 · DOI
  126. Raftopoulos, 2016, Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies, Support. Care Cancer, 24, 1517
  127. Braekkan, 2010, Hematocrit and risk of venous thromboembolism in a general population. The Tromso study, Haematologica, 95, 270, 10.3324/haematol.2009.008417 · DOI · Paper page
  128. Greenwald, 2003, The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly, Mol. Cell, 11, 605, 10.1016/S1097-2765(03)00094-7 · DOI · Paper page
  129. Makanji, 2011, Generation of a specific activin antagonist by modification of the activin A propeptide, Endocrinology, 152, 3758, 10.1210/en.2011-1052 · DOI
  130. Aykul, 2017, Biochemical and cellular analysis reveals ligand binding specificities, a molecular basis for ligand recognition, and membrane association-dependent activities of cripto-1 and cryptic, J. Biol. Chem., 292, 4138, 10.1074/jbc.M116.747501 · DOI
  131. Souza, 2008, Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators, Mol. Endocrinol., 22, 2689, 10.1210/me.2008-0290 · DOI · Paper page
  132. Wu, 2010, Identification and analysis of type II TGF- receptors in BMP-9-induced osteogenic differentiation of C3H10T1/2 mesenchymal stem cells, Acta Biochim, Biophys. Sin. (Shanghai)., 42, 699, 10.1093/abbs/gmq075 · DOI
  133. Kienast, 2016, Rapid activation of bone morphogenic protein 9 by receptor-mediated displacement of pro-domains, J. Biol. Chem., 291, 3395, 10.1074/jbc.M115.680009 · DOI
  134. Townson, 2012, Specificity and structure of a high affinity ALK1 complex, J.Biol.Chem., 287, 27313, 10.1074/jbc.M112.377960 · DOI · Paper page
  135. Koncarevic, 2012, A novel therapeutic approach to treating obesity through modulation of TGFβ signaling, Endocrinology, 153, 3133, 10.1210/en.2012-1016 · DOI · Paper page
  136. Hashimoto, 2000, Difference between follistatin isoforms in the inhibition of activin signalling: activin neutralizing activity of follistatin isoforms is dependent on their affinity for activin, Cell. Signal., 12, 565, 10.1016/S0898-6568(00)00099-1 · DOI
  137. Smith, 2015, Myostatin neutralization results in preservation of muscle mass and strength in preclinical models of tumor-induced muscle wasting, Mol. Cancer Ther., 14, 1661, 10.1158/1535-7163.MCT-14-0681 · DOI · Paper page
  138. Pirruccello-Straub, 2018, Blocking extracellular activation of myostatin as a strategy for treating muscle wasting, Sci. Rep., 8, 2292, 10.1038/s41598-018-20524-9 · DOI · Paper page
  139. Dagbay, 2020, Structural basis for specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015, J. Biol. Chem., 10.1074/jbc.RA119.012293 · DOI
  140. Andre, 2017, Skelet. Muscle, 7, 25, 10.1186/s13395-017-0141-y · DOI · Paper page
  141. Komrokji, 2018, Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial, Lancet Haematol., 10.1016/S2352-3026(18)30002-4 · DOI
  142. Rooks, 2017, Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy, J. Cachexia, Sarcopenia Muscle., 8, 727, 10.1002/jcsm.12205 · DOI · Paper page
  143. Hanna, 2019, Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial, Lancet Neurol., 18, 834, 10.1016/S1474-4422(19)30200-5 · DOI · Paper page
  144. Krivickas, 2009, Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029, Muscle Nerve, 39, 3, 10.1002/mus.21200 · DOI · Paper page
  145. Jameson, 2012, Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer, J. Clin. Oncol., 30, 2516, 10.1200/jco.2012.30.15_suppl.2516 · DOI

Cited by

See all 62

Metadata

Authors
Lodberg, A.
Venue
Cytokine & Growth Factor Reviews
Publisher
Elsevier BV
Published
2021-08
Volume
60
Pages
1-17
ISSN
1359-6101 (ISSN-L)
OpenAlex
W3154035165
Cited by
62
References
39
FWCI
0.84
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Elsass Foundation
  • Danish Lung Association
  • Engineer Frode V Nyegaard and Wife's Foundation
  • Novo Nordisk Foundation
  • AP Moller Fonden
  • Dagmar Marshall Fund

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Principles of the activin receptor signaling pathway and its inhibition. https://app.cochat.ai/papers/10.1016/j.cytogfr.2021.04.001
The paper
Lodberg, A. (2021). Principles of the activin receptor signaling pathway and its inhibition. Cytokine & Growth Factor Reviews. https://doi.org/10.1016/j.cytogfr.2021.04.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.